Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akari Therapeutics (AKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,858
  • Shares Outstanding, K 15,260
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,400 K
  • 36-Month Beta -5.94
  • Price/Sales 265,592.60
  • Price/Cash Flow N/A
  • Price/Book 3.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +1,427,242.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.63 +7.98%
on 12/13/18
1.92 -8.33%
on 12/06/18
+0.01 (+0.57%)
since 11/16/18
3-Month
1.62 +8.64%
on 10/29/18
2.95 -40.34%
on 10/01/18
-0.25 (-12.44%)
since 09/18/18
52-Week
1.62 +8.64%
on 10/29/18
4.89 -64.01%
on 12/27/17
-2.54 (-59.07%)
since 12/18/17

Most Recent Stories

More News
Akari Therapeutics Announces New Data Highlighting Differentiation of Drug Candidate Coversin

-- Planned introduction of patient-friendly pen auto-injector in 2019 designed to increase comfort and convenience of treatment across the entire Akari subcutaneous program

AKTX : 1.76 (unch)
Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit

Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA)

AKTX : 1.76 (unch)
Akari Announces Third Quarter 2018 Financial Results and Business Highlights

-- Two clinical programs expected to report initial data in first quarter 2019

AKTX : 1.76 (unch)
Akari Announces Second Quarter 2018 Financial Results and Business Highlights

Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases where...

AKTX : 1.76 (unch)
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC

Akari Therapeutics, Plc ("Akari" or the "Company") (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and...

AKTX : 1.76 (unch)
Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

Akari Therapeutics, Plc (NASDAQ:AKTX) ("Akari" or "the Company"), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and...

AKTX : 1.76 (unch)
Akari Therapeutics Announces New Preclinical Rheumatoid Arthritis Data and New Clinical Data in Patients with Bullous Pemphigoid, Highlighting Potential Advantages of Coversin's bifunctional activity inhibiting both the Complement and Leukotriene Inflammatory Pathways

-- Combined inhibition of LTB4 and C5 by Coversin showed reversal of disease symptoms in preclinical rheumatoid arthritis (RA) model

AKTX : 1.76 (unch)
Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brady Corporation (NYSE:BRC),...

AKTX : 1.76 (unch)
SRNE : 2.23 (-9.72%)
MTGE : 19.80 (-0.25%)
BRC : 41.60 (+1.34%)
NEWR : 81.40 (+1.40%)
JLL : 131.66 (+3.78%)
Blog Exposure - Tetraphase Pharma Announced Data Presentations from IGNITE4 Study at 28th European Congress of Clinical Microbiology and Infectious Diseases

Stock Monitor: Akari Therapeutics Post Earnings Reporting

AKTX : 1.76 (unch)
TTPH : 1.39 (-4.79%)
Analysis: Positioning to Benefit within ForeScout Technologies, CommerceHub, Newtek Business Services, Credit Acceptance, Akari Therapeutics, and Brady -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ForeScout Technologies, Inc....

NEWT : 17.20 (-0.52%)
AKTX : 1.76 (unch)
CACC : 378.06 (+3.03%)
BRC : 41.60 (+1.34%)
CHIAV : 13.53 (+12.75%)
CHUBA : 22.73 (+0.04%)
FSCT : 24.61 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AKTX with:

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

2nd Resistance Point 1.83
1st Resistance Point 1.79
Last Price 1.76
1st Support Level 1.69
2nd Support Level 1.63

See More

52-Week High 4.89
Fibonacci 61.8% 3.64
Fibonacci 50% 3.25
Fibonacci 38.2% 2.87
Last Price 1.76
52-Week Low 1.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar